Posts

Smart Cancer Resources & Research Guide 2026: A Patient-First Map of Diagnosis, Biomarkers, Treatment, Immunotherapy, Resistance & Integrative Oncology

Image
OneDayMD Cancer Resource Library · Network Index · Published September 17, 2026 · Last reviewed and updated September 18, 2026 (v1.1) Cancer information is no longer confined to a single textbook, treatment guideline, or hospital website — and cancer guides should not be limited to oncologists. Modern oncology now spans pathology, staging, molecular biomarkers, precision medicine, prevention, surgery, radiation, chemotherapy, targeted therapy, immunotherapy, cellular therapy, cancer metabolism, treatment resistance, supportive care, and clinical research. This OneDayMD guide brings those subjects together in one navigable resource. Rather than hundreds of disconnected articles, it offers a pathway through the evidence and links directly to deeper OneDayMD, SmartCancer, and Cancer Advisor resources. Quick Answer This page is a map, not a single treatment guide — it connects the OneDayMD network's cancer content by the question you're actually asking. Newly diagnosed...
Post a Comment
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Image
Medically Reviewed by: OneDayMD Editorial Team | Evidence Synthesis & Safety Review | Last Updated: August 2026 Quick Answer Ivermectin, fenbendazole, and mebendazole are antiparasitic drugs with laboratory evidence of anticancer activity.  The pharmacological rationale is real and merits continued, properly controlled trial investment. Patients should discuss any interest in these agents openly with their oncology team rather than self-administering veterinary or compounded formulations.  This article separates the genuine research question from the unverified claims, and outlines what to discuss with an oncology team before considering any of these agents. Background: Ivermectin and the benzimidazole anthelmintics fenbendazole and mebendazole have attracted sustained public attention as repurposed anticancer agents, driven substantially by social media case testimonials and a small number of peer-reviewed mechanistic studies. Objective: To synthesize the precl...
Post a Comment
Read more

Ivermectin, Fenbendazole & Mebendazole for Cancer: 2026 Evidence Guide

Image
A Master Guide & Reference — Evidence, Mechanisms, Clinical Trials, Case Series, Safety, and Protocols By Dr. Frank Yap, MD · Originally published July 2025 · Reviewed and substantially updated September 2026 Quick Answer Ivermectin, fenbendazole, mebendazole, and niclosamide are antiparasitic drugs with laboratory and animal evidence of anticancer activity, plus a growing body of patient-reported case reports. None of the four is an approved or established cancer treatment.  Mebendazole and niclosamide have gone further into human oncology trials than fenbendazole, but results remain mixed or inconclusive. This guide organizes the mechanistic evidence, clinical trial data, 760+ compiled case reports, safety findings, and the updated Joe Tippens Protocol into one evidence-tiered reference — with the regulatory and safety picture current as of September 2026. Table of Contents Front Matter Introduction: The Joe Tippens Story Part I — The Case for Drug Repurposing...
Post a Comment
Read more

Archive

Show more